Zevra reports Q2 2026 results as MIPLYFFA revenue grows and EU review continues

Zevra Therapeutics reported financial results and a corporate update for the quarter ended June 30, 2026, in a release dated August 5, 2026, with a same-day conference call scheduled for 4:30 p.m. ET.

On the regulatory front, the company said it is pursuing access to arimoclomol for people living with NPC in Europe and has submitted a request for the re-examination of its Marketing Authorisation Application.¹ Separately, as of June 30, 2026, 132 patients were enrolled in the company's global Expanded Access Program.¹ In the U.S., Zevra received 14 new MIPLYFFA prescription enrollment forms for NPC during the quarter, bringing the cumulative total to 184 since launch, while market access held at 69% of covered lives.¹ The company also said it strengthened its intellectual property position for MIPLYFFA with an Orange Book listing through 2041.¹

On the pipeline side, Zevra enrolled four more patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome during the quarter, bringing total enrollment to 66 patients with three confirmed events.¹ The company said it expects to continue engagement with the FDA in the second half of the year to explore pathways to accelerate clinical development.¹

Financially, net revenue was $39.7 million for the quarter, including $30.2 million from MIPLYFFA, $0.2 million from OLPRUVA, $9.0 million in net EAP reimbursements, and $0.3 million in past-due AZSTARYS royalties, up $13.8 million from $25.9 million in Q2 2025.¹ Cash, cash equivalents and investments totaled $260.2 million as of June 30, 2026.¹ The company said it believes its available financial resources are sufficient to execute on its strategic priorities independent from the capital markets.¹